Assembly Biosciences To Highlight Pipeline Progress In HBV And HDV At The 2023 International HBV Meeting
-- Two oral presentations and one poster will feature new data from the Company's hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs --
SOUTH